Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Sarcoma 7Gastrointestinal Stromal Tumors 4Hemangiosarcoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Melanoma 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Sarcoma, Alveolar Soft Part 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Liver Neoplasms 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1

Interventions

Ibandronic Acid 8Gemcitabine 8Doxorubicin 6Cyclophosphamide 6Zoledronic Acid 5Radiation 4Nivolumab 4Irinotecan 4pembrolizumab 3Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Docetaxel 3Denosumab 3Cisplatin 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3regorafenib 2pegfilgrastim 2Tranexamic Acid 2Trabectedin 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Quality of Life 2Proton Therapy 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × spartalizumab × Sarcoma × Clear all
NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Assaf-Harofeh Medical Center

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡